2.Jun Li, Lei Chen, Nan Liu, Shengnan Li, Yanli Hao*, Xiaoning Zhang*. 2015. EGF-coated nano-dendriplexes for tumor targeted nucleic acid delivery in vivo. Drug Delivery, 25:1-8.

3.Yanli Hao*, Lan Wang, Jun Li, Nan Liu, Jinfeng Feng, Mojiao Zhao, Xiaoning Zhang*. 2015. Enhancement of solubility, transport across MDCK monolayer and oral absorption of pranlukast by preparing pranlukast-phospholipid complex. J. Biomedical Nanotechnology, 11(3): 469-477(9)

4.Anil Kumar, Fei Chen, Anbu Mozhi,Xu Zhang, Yuanyuan Zhao, Xiangdong Xue, Yanli Hao, Xiaoning Zhang, and Xing-Jie Liang*. 2013. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale, 5:8307-8325.

5.Zhe Yin, Nan Liu, Mingshu Ma, Lan Wang, Xing-Jie Liang, Yanli Hao*, Xiaoning Zhang*. 2012. A novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA and activated PAMAM dendrimers, In J Nanomedicine 7, pp 4625-4635.

6.Nan Liu, Yanli Hao*, Zhe Yin, Mingshu Ma, Lan Wang, Xiaoning Zhang*. 2012. Self-Assembled Human Serum Albumin-Coated Complexes for Gene Delivery with Improved Transfection. Die Pharmazie, 67(2): 174-181.

Mingshu Ma, Yanli Hao*, Nan Liu, Zhe Yin, Lan Wang, Xing-Jie Liang, Xiaoning Zhang*. 2012. A novel lipid-based nano-micelle of docetaxel: evaluated antitumor efficiency and biodistribution with optical imaging in vivo. In J Nanomedicine,7, pp 3389-3398.

7.Lan Wang, Yanli Hao*, Nan Liu, Zhe Yin, Mingshu Ma, Xiaoning Zhang*. 2012. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method. Drug Development and Industrial Pharmacy, 38(11):1381-1389.

8.Chunlei Li, Jingxia Cui, Yingui Li, Caixia Wang, Yanhui Li, Lan Zhang, Li Zhang, Wenmin Guo, Jinxu Wang, Hongwu Zhang, Yanli Hao, Yongli Wang. 2008. Copper ion-mediated liposomal encapsulation of mitoxantrone:The role of anions in drug loading, retention and release. Eur. J Pharm. Sci, 34(4-5):333-344.

Jingxia Cui, Chunlei Li, Yanhui Li, Caixia Wang, Li Zhang, Lan Zhang, Yanli Hao,Yongli Wang. 2007. Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? J Controlled Release, 118(2):204-215.

9.Aijun Hao, Yingjie Deng, Tiefu Li, Xubin Suo, Yanhai Cao, Yanli Hao, Yong Zhang. 2006. Degradation kinetics of fluorouracil-acid-dextran conjugate in aqueous solution. Drug Development and Industrial Pharmacy, 32(6):757-763.

10.Yanli Hao, Yingjie Deng, Yan Chen, Kezhan Wang, Aijun Hao and Yong Zhang. 2005. In vitro cytotoxicity, in vivo biodistribution and anti-tumor effect of PEGlyated liposome containing topotecan. J Pharmacy and Pharmacology, 57: 1279-1287.

11.Yanli Hao, Yingjie Deng, Yan Chen, Xiumin Wang, Haijun Zhong and Xubin Suo. 2005. In-Vitro and In-Vivo Studies of Different Liposomes Containing Topotecan. Archives of Pharmacal Research, 28(5): 626-635.

12.Yanli Hao, Yingjie Deng, Yan Chen and Youcai Hu. Synthesis 3-4-2-hydroxyl-(1-methyl ethylamine) propyl oxygen}phenyl}propionic acid cetylester as Potential Ligand for Liposome Targeting to Ischemic Myocardium. Chinese Chemical Letters, 16(8):1004-1006.

13.Yan Chen, Yingjie Deng, Yanli Hao. 2005. Surface modification of liposomes for selective cardiomyocytes targeting in vitro. Die Pharmazie, 60(3): 238-240.

14.Yan Chen, Yingjie Deng, Yanli Hao, Aijun Hao, Haijun Zhong and Xiumin Wang. 2005. Uptake of liposomes by cultured cardiomyocytes. Die Pharmazie, 60(11):844-848.